Anixa Biosciences Secures Mexican Patent for Breast Cancer Vaccine, Expands Intellectual Property Portfolio.

Anixa Biosciences has secured a new patent in Mexico for its breast cancer vaccine technology, expanding its intellectual property portfolio. The company operates in the biotechnology sector, focusing on cancer vaccines and CAR-T therapies. Despite strong financial ratios, Anixa faces challenges with negative earnings and high volatility. The vaccine targets human alpha-lactalbumin, a protein unexpectedly expressed in certain breast cancer types, aiming to enhance the immune system's ability to prevent tumor growth.